Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucoma

Press ReleaseNicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucoma Denali Phase 3 co-funded equally by Nicox and Ocumension TherapeuticsPhase

Related Keywords

New York ,United States ,Valbonne ,Provence Alpes Côd Azur ,France ,Paris ,France General ,Hong Kong ,United Kingdom ,China ,Chinese ,Gavin Spencer ,Victor Liu ,Enregistrement Universel ,Pharma Bio ,Kepler Cheuvreux Damien Choplain ,Sophia Antipolis ,Sophie Baumont ,Cantor Fitzgerald Louise Chen ,States Europe ,Garnier Co Victor Floch Paris ,Head Of Corporate Development ,Allergan Inc ,Lifesci Advisors ,National Medical Products Administration ,Eyevance Pharmaceuticals ,Edison Investment Research Pooya Hemami London ,Announces First Patient ,Euronext Paris ,Denali Phase ,New Drug Application ,National Medical Products ,Chief Business Officer ,Mont Blanc Phase ,China Phase ,Chief Executive Officer ,Market Capitalization ,Southeast Asia ,Ocumension Therapeutics ,Southeast Asian ,Mid Caps ,Victor Floc H ,Louise Chen ,Investment Research ,Pooya Hemami ,Damien Choplain ,Vice President ,Chief Business ,Corporate Development ,Sci Advisors ,French Autorit ,Des March ,Nicox ,Nnounces ,First ,Patient ,Gscreened ,Ngoing ,Denali ,Hase ,Trial ,Glaucoma ,